ESPR Esperion Therapeutics Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Esperion Therapeutics, Inc. (“Esperion” or “the Company”) (NASDAQGM:ESPR) concerning possible violations of federal securities laws.

On May 2, 2018, Esperion announced results from its second Phase 3 study for its cholesterol-lowering medication bempedoic acid. Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group. On this news, Esperion’s share price fell from a close of $70.50 per share on May 1, 2018, to a close of $45.75 per share the following day. To obtain additional information, go to:

http://www.zlk.com/pslra-d/esperion-therapeutics-investigation

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
09/05/2018

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results a...

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a...

March 10, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s D...

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Poten...

March 3, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results...

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours afte...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Esperion to Participate in The 2026 Citizens Life Sciences Conference ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. About Esperion TherapeuticsEsperion Th...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Mar...

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expir...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch